万维书刊网微信二维码

扫微信,关注编辑QQ!

您的位置:万维书刊网 >>sci/e期刊大全 >>医药卫生2>>药学
您的位置:万维书刊网 >>sci/e期刊大全 >>医药卫生3>>生化研究方法

ASSAY AND DRUG DEVELOPMENT TECHNOLOGIES《验定与药品开发技术》 (官网投稿)

简介
  • 期刊简称ASSAY DRUG DEV TECHN
  • 参考译名《验定与药品开发技术》
  • 核心类别 SCIE(2024版), 目次收录(维普),外文期刊,
  • IF影响因子1.738
  • 自引率6.20%
  • 主要研究方向医学-BIOCHEMICAL RESEARCH METHODS 生化研究方法;PHARMACOLOGY & PHARMACY 药学

主要研究方向:

等待设置主要研究方向
医学-BIOCHEMICAL RESEARCH METHODS 生化研究方法;PHARMACOLOGY & PHARMACY 药学

ASSAY AND DRUG DEVELOPMENT TECHNOLOGIES《验定与药品开发技术》(一年8期). ASSAY and Drug Development Technologies focuses on early-stage screening techniques and...[显示全部]
征稿信息

万维提示:

1、投稿方式:在线投稿

2期刊网址:

https://home.liebertpub.com/publications/assay-and-drug-development-technologies/118

3投稿网址:https://mc.manuscriptcentral.com/assay

4、官网邮箱:assay_eo@liebertpub.com(编辑部)

5、期刊刊期:一年出版8期。

2021年8月19日星期

                                 

 

投稿须知【官网信息】

 

ASSAY and Drug Development Technologies

For Authors

Journal Information

Manuscript Submission Site: https://mc.manuscriptcentral.com/assay

Editorial Office Contact: assay_eo@liebertpub.com

Support Contact: prosupport@liebertpub.com

Journal Model: Hybrid (Open Access Option)

Blinding: Single Blind

File formatting requirement stage: On revision. Format neutral on original submission.

Instant Online Option (immediate publication of accepted version): No

Average time to initial decison: 31 days

About the Journal

ASSAY and Drug Development Technologies focuses on early-stage screening techniques and tools that optimize the identification of novel leads and targets for new drug development, running the spectrum from nanotechnology through cellular imaging. Case studies are presented, and technology applications are extensive. Articles published in ASSAY and Drug Development Technologies emphasize methodologies and technologies to accelerate drug discovery.

Included topics are: State-of-the-art research, methods, materials, and protocols in assay design and target development; High throughput screening; High throughput chemistry; Lab automation; Data analysis and information management; Microplate standards; Screen design and advanced technology; Protein structure and function; Compound library generation; Bioinformatics and data mining; Validation strategies; Biosensors; Detection technologies; Miniaturization and nanotechnology; Protein–protein interaction as novel drug targets; Novel screening methods with high information content; Metabolically engineered cells and organisms; Imaging technologies for live cells, tissues, and small animals; and Virtual screening.

Manuscripts submitted to this Journal must not be under consideration elsewhere.

Manuscript Types and Guidelines

Original Article

3,000-word limit

Unstructured abstract of no more than 250 words

Maximum total of eight (8) figures and/or tables

Protocol Table is required

 

Review Articles

8,000-word limit

Unstructured abstract of no more than 250 words

Maximum total of ten (10) figures and/or tables

 

Perspectives

1,500-word limit

Unstructured abstract of no more than 100 words

An Introduction and a Conclusion are mandatory

Maximum total of three (3) figures and/or tables

Maximum of 25 references

 

Editorials

1,000-word limit

No abstract

No figures or tables

Maximum of 10 references

 

Letter to the Editor

500-word limit

No abstract

May include one figure OR table

Reference citations are identical in style to those of full original articles, but should not exceed five (5).

Word limits do NOT pertain to the abstract, disclosure statements, author contribution statements, funding information, acknowledgments, tables, figure legends, or references.

ASSAY and Drug Development Technologies welcomes format-neutral manuscripts for first-time submissions. Newly submitted manuscripts will not be un-submitted for formatting issues.  However, after the initial peer review process, revised submissions must follow correct journal formatting and file guidelines, as described below in the Instructions for Authors. Please note that there are certain compulsory elements (ie: IRB approvals, author disclosures, etc.) for all new submissions. Manuscripts submitted without this information will be un-submitted and the submitting author will be asked to add the required components.

……

更多详情:

https://home.liebertpub.com/publications/assay-and-drug-development-technologies/118/for-authors


  • 万维QQ投稿交流群    招募志愿者

    版权所有 Copyright@2009-2015豫ICP证合字09037080号

     纯自助论文投稿平台    E-mail:eshukan@163.com


投稿问答最小化  关闭